Rajani Associates has played a pivotal role in advising Beaufond Industries Limited during the resolution process of Kobo Biotech Limited. As the successful resolution applicant, Beaufond Industries submitted a comprehensive resolution plan valued at approximately ₹70 crore. This plan was presented to the Committee of Creditors on March 4, 2026, received their approval on March 17, 2026, and was subsequently sanctioned by the National Company Law Tribunal (NCLT) on May 11, 2026.
The legal expertise of Rajani Associates was instrumental in navigating the complexities of the resolution plan and the accompanying composite scheme of amalgamation and arrangement. This approved plan includes the strategic merger of Beaufond Industries with Kobo Biotech, the demerger of the Active Pharmaceutical Ingredient (API) business into a new separate entity, and the rebranding of the surviving entity as Beaufond Ltd.
The transaction was spearheaded by Ashish Parwani, a Senior Partner at the firm, with substantial contributions from Principal Associates Gitika Makhija and S Shivganesh. Their combined efforts ensured a seamless advisory process, facilitating a smooth transition and integration as outlined in the resolution plan.
Rajani Associates’ guidance underscores their commitment to providing top-tier legal support in high-stakes corporate resolutions, showcasing their proficiency in handling complex legal frameworks and corporate restructurings. This transaction not only highlights their expertise but also reinforces their standing in the legal advisory domain, particularly in insolvency and bankruptcy proceedings.
For those interested in having their legal deals, columns, or press releases featured on Bar & Bench, please complete the submission form available here.
